Current advances in the treatment of neovascular age-related macular degeneration
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current advances in the treatment of neovascular age-related macular degeneration
Authors
Keywords
-
Journal
Expert Opinion on Drug Delivery
Volume 14, Issue 2, Pages 273-282
Publisher
Informa UK Limited
Online
2016-07-20
DOI
10.1080/17425247.2016.1213240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2016) Glenn J. Jaffe et al. OPHTHALMOLOGY
- Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
- (2016) Maureen G. Maguire et al. OPHTHALMOLOGY
- mTOR pathway activation in age-related retinal disease
- (2016) Chen Zhao et al. Aging-US
- Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial
- (2015) Emily Y. Chew et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Current phase 1/2 research for neovascular age-related macular degeneration
- (2015) Paula E. Pecen et al. CURRENT OPINION IN OPHTHALMOLOGY
- Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration
- (2015) Karl G. Csaky et al. OPHTHALMOLOGY
- Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment
- (2015) Ninel Z. Gregori et al. Ophthalmic Surgery Lasers & Imaging Retina
- One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD
- (2014) Jennifer I Lim et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Drugs in Phase II clinical trials for the treatment of age-related macular degeneration
- (2014) Michael John Tolentino et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ocular Hypertension and Intraocular Pressure Asymmetry After Intravitreal Injection of Anti–Vascular Endothelial Growth Factor Agents
- (2014) Suzann Pershing et al. Ophthalmic Surgery Lasers & Imaging Retina
- Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
- (2013) Ronald Danis et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
- (2013) Sanjay Sharma et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- An update on the pharmacotherapy of neovascular age-related macular degeneration
- (2013) K Bailey Freund et al. EXPERT OPINION ON PHARMACOTHERAPY
- Liposomes and nanotechnology in drug development: focus on ocular targets
- (2013) Miki Honda et al. International Journal of Nanomedicine
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- (2013) Usha Chakravarthy et al. LANCET
- Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
- (2013) H. I. Hurwitz et al. ONCOLOGIST
- Epimacular Brachytherapy for Neovascular Age-related Macular Degeneration (CABERNET)
- (2013) Timothy L. Jackson et al. OPHTHALMOLOGY
- Stereotactic Radiotherapy for Neovascular Age-related Macular Degeneration
- (2013) Timothy L. Jackson et al. OPHTHALMOLOGY
- Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
- (2013) Uday B. Kompella et al. PROGRESS IN RETINAL AND EYE RESEARCH
- MACULAR EPIRETINAL BRACHYTHERAPY IN TREATED AGE-RELATED MACULAR DEGENERATION (MERITAGE)
- (2013) Robert Petrarca et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Initial Exploration of Oral Pazopanib in Healthy Participants and Patients With Age-Related Macular Degeneration
- (2013) Megan M. McLaughlin et al. JAMA Ophthalmology
- Reservoir-based drug delivery systems utilizing microtechnology
- (2012) Cynthia L. Stevenson et al. ADVANCED DRUG DELIVERY REVIEWS
- Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study
- (2012) Peter A. Campochiaro et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
- (2012) Andreas Stahl et al. ANGIOGENESIS
- Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid
- (2012) A T Fung et al. EYE
- Safety and Biodistribution of an Equine Infectious Anemia Virus-Based Gene Therapy, RetinoStat®, for Age-Related Macular Degeneration
- (2012) Katie Binley et al. HUMAN GENE THERAPY
- Tolerability and Pharmacokinetics of Intravitreal Sirolimus
- (2012) Sri Mudumba et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Bevacizumab and Triamcinolone Acetonide for Choroidal Neovascularization Due to Age-Related Macular Degeneration Unresponsive to Antivascular Endothelial Growth Factors
- (2012) Daniele Veritti et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Evaluation of the siRNA PF-04523655 versus Ranibizumab for the Treatment of Neovascular Age-related Macular Degeneration (MONET Study)
- (2012) Quan Dong Nguyen et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Macular Epiretinal Brachytherapy in Treated Age-related Macular Degeneration (MERITAGE)
- (2012) Robert Petrarca et al. OPHTHALMOLOGY
- Epimacular Brachytherapy for Neovascular Age-related Macular Degeneration
- (2012) Pravin U. Dugel et al. OPHTHALMOLOGY
- Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
- (2012) Gui-shuang Ying et al. OPHTHALMOLOGY
- INHIBITORY ACTIVITY OF RANIBIZUMAB, SORAFENIB, AND PAZOPANIB ON LIGHT-INDUCED OVEREXPRESSION OF PLATELET-DERIVED GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR A AND THE VASCULAR ENDOTHELIAL GROWTH FACTOR A RECEPTORS 1 AND 2 AND NEUROPILIN 1 AND 2
- (2012) Marcus Kernt et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Anti-VEGF Treatment Strategies for Wet AMD
- (2012) Jaclyn L. Kovach et al. Journal of Ophthalmology
- Ocular Complications After Anti–Vascular Endothelial Growth Factor Therapy in Medicare Patients With Age-Related Macular Degeneration
- (2011) Shelley Day et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Suppression of Choroidal Neovascularization by Intravitreal Injection of Liposomal SU5416
- (2011) Miki Honda ARCHIVES OF OPHTHALMOLOGY
- Extended Release of Bevacizumab by Thermosensitive Biodegradable and Biocompatible Hydrogel
- (2011) Chau-Hui Wang et al. BIOMACROMOLECULES
- Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
- (2011) E. M. Becerra et al. CURRENT DRUG TARGETS
- Micro-patterned drug delivery device for light-activated drug release
- (2011) Raiyan T. Zaman et al. LASERS IN SURGERY AND MEDICINE
- Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage
- (2011) Ashish Thakur et al. MICROVASCULAR RESEARCH
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Radiation Treatment for Age-Related Macular Degeneration
- (2011) Ruwan A. Silva et al. Seminars in Ophthalmology
- Multi-task learning for cross-platform siRNA efficacy prediction: an in-silico study
- (2010) Qi Liu et al. BMC BIOINFORMATICS
- Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration
- (2010) Roger A. Sabbadini BRITISH JOURNAL OF PHARMACOLOGY
- Adeno-Associated Vector (Type 8)-Mediated Expression of Soluble Flt-1 Efficiently Inhibits Neovascularization in a Murine Choroidal Neovascularization Model
- (2010) Tsutomu Igarashi et al. HUMAN GENE THERAPY
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice
- (2010) Chen Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation
- (2010) Adrianne L. Myers et al. JOURNAL OF PEDIATRIC SURGERY
- Stereotactic targeting and dose verification for age-related macular degeneration
- (2010) Michael Gertner et al. MEDICAL PHYSICS
- Characteristics of Patients Losing Vision after 2 Years of Monthly Dosing in the Phase III Ranibizumab Clinical Trials
- (2010) Philip J. Rosenfeld et al. OPHTHALMOLOGY
- A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATION
- (2010) Robert B Nussenblatt et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Intravitreal poly(l-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases
- (2010) Namdev B. Shelke et al. Drug Delivery and Translational Research
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy
- (2009) Neil M. Bressler ARCHIVES OF OPHTHALMOLOGY
- Endophthalmitis after intravitreal injections
- (2009) Stephen G Schwartz et al. EXPERT OPINION ON PHARMACOTHERAPY
- Recent Perspectives in Ocular Drug Delivery
- (2009) Ripal Gaudana et al. PHARMACEUTICAL RESEARCH
- TWELVE-MONTH SAFETY AND VISUAL ACUITY RESULTS FROM A FEASIBILITY STUDY OF INTRAOCULAR, EPIRETINAL RADIATION THERAPY FOR THE TREATMENT OF SUBFOVEAL CNV SECONDARY TO AMD
- (2009) MARCOS P. ÁVILA et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
- (2009) FARZIN FOROOGHIAN et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATION
- (2009) MAJID ABRISHAMI et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
- (2008) M P Avila et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization
- (2008) Sergio Caballero et al. EXPERIMENTAL EYE RESEARCH
- Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization
- (2008) Bing Xie et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors
- (2008) Magali Saint-Geniez et al. PLoS One
- The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration
- (2008) Salvatore Grisanti et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Nanoparticles: pharmacological and toxicological significance
- (2007) C Medina et al. BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search